Ingredient or product comparison
[Full Keyword]: Clinical vs Preclinical Comparison
In vitro (2013 PLOS ONE) Isolated human dermal papilla cells 1–10 μM (0.034–0.34% equivalent) Cell proliferation, β-catenin expression 170% increase in proliferation; 2.3× β-catenin upregulation Mechanism is clear. Direct dermal papilla activation. Translates
This source-based comparison does not add ratings or recommend a winner.
- In vitro (2013 PLOS ONE)
- Isolated human dermal papilla cells
- 1–10 μM (0.034–0.34% equivalent)
- Cell proliferation, β-catenin expression
- 170% increase in proliferation; 2.3× β-catenin upregulation
- Mechanism is clear. Direct dermal papilla activation. Translates to follicle phase extension in theory.
- Ex vivo (2015 Arch Dermatol Res)
- Human scalp follicles in organ culture
- 1 μM (0.034% equivalent)
- Follicle length after 6 days
- 22.3% increase vs untreated control
- Strongest evidence for anagen extension. Organ culture closely mimics in vivo physiology.
- Human pilot trial (2007)
- 30 participants, androgenetic alopecia
- 0.5% topical solution, twice daily, 12 weeks
- Hair density (hairs/cm²)
- +8 hairs/cm² vs +2 placebo
- Statistically significant, clinically modest. Doesn't distinguish terminal vs vellus hairs.
- Formulation study (2020 Int J Pharm)
- Ex vivo human skin (Franz diffusion cell)
- 1% in nanostructured lipid carriers
- Dermal penetration depth and concentration
- 3.2× penetration vs aqueous solution
- Delivery vehicle matters. Standard solutions may not reach dermal papilla layer effectively.
- Stability analysis (2019)
- GHK-Cu solutions stored at varied temps
- 0.1–2% in buffered saline
- Potency retention over 90 days
- 40–60% degradation at 25°C; <10% at 2–8°C
- Refrigeration mandatory. Oxidized peptide loses activity entirely.